Your browser is no longer supported. Please, upgrade your browser.
Settings
PFE Pfizer Inc. daily Stock Chart
PFE [NYSE]
Pfizer Inc.
IndexDJIA S&P500 P/E19.80 EPS (ttm)1.83 Insider Own0.10% Shs Outstand5.96B Perf Week-0.39%
Market Cap215.41B Forward P/E11.78 EPS next Y3.07 Insider Trans-7.69% Shs Float5.85B Perf Month1.26%
Income11.05B PEG3.03 EPS next Q0.74 Inst Own73.20% Short Float1.06% Perf Quarter-0.47%
Sales52.67B P/S4.09 EPS this Y49.80% Inst Trans-1.19% Short Ratio2.90 Perf Half Y-0.82%
Book/sh11.78 P/B3.07 EPS next Y3.96% ROA12.80% Target Price39.86 Perf Year9.68%
Cash/sh1.92 P/C18.86 EPS next 5Y6.54% ROE33.40% 52W Range32.32 - 39.43 Perf YTD-0.17%
Dividend1.36 P/FCF29.79 EPS past 5Y7.90% ROI9.90% 52W High-8.04% Beta0.91
Dividend %3.76% Quick Ratio1.00 Sales past 5Y-0.80% Gross Margin79.20% 52W Low12.19% ATR0.38
Employees90200 Current Ratio1.30 Sales Q/Q1.00% Oper. Margin24.80% RSI (14)50.95 Volatility0.97% 0.95%
OptionableYes Debt/Eq0.58 EPS Q/Q14.80% Profit Margin41.30% Rel Volume0.68 Prev Close36.16
ShortableYes LT Debt/Eq0.45 EarningsJul 31 BMO Payout35.60% Avg Volume21.28M Price36.26
Recom2.50 SMA200.32% SMA500.70% SMA2000.88% Volume4,994,893 Change0.28%
Jun-08-18Initiated Cantor Fitzgerald Overweight $45
Apr-05-18Downgrade Barclays Overweight → Equal Weight $41 → $38
Jan-29-18Reiterated SunTrust Hold $33 → $40
Sep-20-17Upgrade Morgan Stanley Equal-Weight → Overweight
Jul-20-17Downgrade Credit Suisse Outperform → Neutral
May-16-17Downgrade Citigroup Neutral → Sell
Dec-02-16Initiated Guggenheim Neutral
Nov-02-16Downgrade Argus Buy → Hold
Oct-13-16Downgrade Jefferies Buy → Hold
Jun-20-16Reiterated Jefferies Buy $42 → $40
May-12-16Initiated Berenberg Hold $38
May-04-16Reiterated UBS Buy $36 → $38
Apr-18-16Resumed Goldman Neutral $35
Apr-07-16Resumed Morgan Stanley Equal-Weight $35
Apr-07-16Resumed JP Morgan Overweight $38
Nov-25-15Upgrade Sun Trust Rbsn Humphrey Reduce → Neutral
Nov-03-15Reiterated Argus Buy $41 → $46
Oct-28-15Reiterated Deutsche Bank Buy $41 → $43
Oct-02-15Upgrade Morgan Stanley Equal-Weight → Overweight $35 → $38
Jul-29-15Reiterated Argus Buy $39 → $41
Jun-19-18 10:18AM  A Gene Therapy Appears To Replace Missing Protein In Muscular Dystrophy Patients Forbes
10:00AM  Pfizer Invites Public To View And Listen To Webcast Of July 31 Conference Call With Analysts Business Wire
Jun-18-18 11:00PM  [$$] Britains flawed medicines regime urgently needs reform Financial Times
07:00AM  FOCUS-How U.S. tax reform rewards companies that shift profit to tax havens Reuters
06:00AM  5 Drug Stocks With Fat Payouts Investopedia
Jun-17-18 06:31AM  Better Buy: Pfizer Inc. vs. Johnson & Johnson Motley Fool
Jun-16-18 06:33AM  Investing Insights: Conference Highlights and Mind the Gap Morningstar
Jun-15-18 08:36PM  25 Blue-Chip Stocks That Mutual Fund Managers Love Most Kiplinger
02:31PM  Cash for NASH: 2 Top Biotech Takeover Targets and 3 Potential Buyers Motley Fool
09:56AM  Can Sprout Pharmas Latest Revival Really Boost VRX Stock? InvestorPlace
Jun-14-18 08:20AM  ViiV Healthcare reports positive results for late-stage HIV trials MarketWatch
Jun-13-18 10:37AM  Merck's (MRK) Keytruda Gets FDA Approval for Cervical Cancer Zacks
08:37AM  This Rare 10.5% Dividend Won't Be Cheap For Long Forbes
06:33AM  Strong Drug Pipeline Bolsters Undervalued Pfizer Morningstar
Jun-12-18 05:00PM  Should You Buy Pfizer Inc (NYSE:PFE) For Its Dividend? Simply Wall St.
08:11AM  Can This Pharma's $14 Billion Bet Succeed? Motley Fool
07:00AM  Pfizer Announces Extension of Zithromax® Antibiotic Donation Program through 2025 to Help Eliminate Worlds Leading Infectious Cause of Blindness Business Wire
06:31AM  3 Stocks to Supplement Your Social Security Income Motley Fool
Jun-11-18 09:06AM  The Zacks Analyst Blog Highlights: Pfizer, Union Pacific, Broadcom, KeyCorp and Ulta Beauty Zacks
07:32AM  A Story Of Devastation And Rebirth: The Former Pfizer Research Labs In Ann Arbor Forbes
Jun-08-18 05:11PM  3 Dividend Stocks Ideal for Retirees Motley Fool
12:20PM  Lilly, Pfizer: Both Unloved but Ready to Grow Barrons.com
11:48AM  Biogen Inks Deal With TMS To Acquire Phase II Stroke Asset Zacks
10:45AM  Top Stock Reports for Pfizer, Union Pacific & Broadcom Zacks
10:27AM  Pharma Stock Roundup: MRK Impresses at ASCO, LLY Gets FDA Nod for Olumiant Zacks
Jun-07-18 05:07PM  In quest to leapfrog Pfizer, Peninsula vaccine company gets $85 million injection American City Business Journals
01:27PM  8 Bitcoin Stocks That You Wont Lose Your Shirt Over InvestorPlace
12:17PM  Pfizer wins appeal against UK fine for epilepsy drug price hike Reuters
11:30AM  [$$] Big Pharma's Tempting Payouts Barrons.com
10:41AM  Pfizer Boosts Venture Capital Efforts, Neuroscience in Focus Zacks
08:00AM  U.S. FDA and European Medicines Agency Accept Regulatory Submissions for Review of Talazoparib for Metastatic Breast Cancer Patients with an Inherited BRCA Mutation Business Wire
Jun-06-18 11:50PM  [$$] Pfizer wins appeal against £84m UK fine over epilepsy drug price Financial Times
11:09PM  [$$] UK tribunal rules against watchdog in Pfizer price-gouging case Financial Times
07:35PM  [$$] Pfizer Ventures Gets $600 Million for Life Sciences Investments The Wall Street Journal
05:51PM  Pfizer Recall of Opioid Overdose Drug is the Latest in a Series of Shortages and Backorders Fortune
02:05PM  Pfizer to pump $600 million in additional funding into biotech startups American City Business Journals
09:06AM  Pfizer pumps $600 million into venture capital arm Reuters
08:28AM  [$$] Pfizer to Invest $600 Million in Its Venture-Capital Arm The Wall Street Journal
08:18AM  Pfizer pumps $600 million into venture capital arm Reuters
08:14AM  Pfizer to invest $600 mln in venture capital arm MarketWatch
08:00AM  Pfizer to Expand Venture Investing with $600 Million Commitment to Pfizer Ventures Business Wire
Jun-05-18 06:08AM  Bristol-Myers (BMY) Reports Data from CheckMate-214 Study Zacks
Jun-04-18 05:37PM  Dacomitinib Shows More than Seven-Month Improvement in Overall Survival Compared to an Established Therapy in Advanced NSCLC with EGFR-Activating Mutations Business Wire
12:01PM  The 8 'Dogs Of The Dow' Continued To Struggle In May Forbes
08:30AM  Today's Research Reports on Trending Tickers: Merck & Co. and Pfizer Inc. ACCESSWIRE
08:00AM  Two-Year Update of Pivotal JAVELIN Merkel 200 Trial Shows Continued Durable Responses with BAVENCIO® (avelumab) PR Newswire
Jun-03-18 07:27PM  The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines Benzinga
06:31AM  3 Reasons for Long-Term Investors to Buy Pfizer Stock Right Now Motley Fool
Jun-01-18 07:00PM  Texas high court rules state must reveal supplier of execution drugs Reuters
05:09PM  FDA Delays Amgen-Allergan Copycat Herceptin, Gives Roche Breathing Room Investor's Business Daily
07:30AM  Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar, TRAZIMERA (trastuzumab) Business Wire
May-31-18 06:46PM  FDA Moves to Make Life Easier for Generic Drug Companies TheStreet.com
02:14PM  Pfizer Inc. Stock Desperately Needs a Viagra-Like Boost InvestorPlace
12:43PM  Why investors ponied up $76M for this company's new approach to Alzheimer's American City Business Journals
10:21AM  Pfizer's Arthritis Drug Gets FDA Nod for Ulcerative Colitis Zacks
May-30-18 05:21PM  Pfizer's Xalkori Gets Breakthrough Status for New Indications Zacks
04:29PM  Dow's Pfizer Jumps As Its Blockbuster Xeljanz Grabs Another Approval Investor's Business Daily
03:52PM  Pfizer Announces U.S. FDA Approves XELJANZ® (tofacitinib) for the Treatment of Moderately to Severely Active Ulcerative Colitis Business Wire
02:01PM  FDA clears Pfizer's Xeljanz for inflammatory bowel disease Reuters
12:36PM  FDA clears Pfizer's Xeljanz for inflammatory bowel disease Reuters
12:08PM  FDA approves Pfizer's Xeljanz to treat ulcerative colitis Reuters
11:29AM  The Pfizer Foundation Announces $5 Million in Grants to Support Women and Families Business Wire
May-29-18 08:00AM  Pfizers XALKORI® (crizotinib) Receives FDA Breakthrough Therapy Designation in Two New Indications Business Wire
May-28-18 11:52PM  [$$] The Heated Quest for Opioid Alternatives The Wall Street Journal
May-25-18 06:32PM  How to Invest in Diabetes Stocks Motley Fool
11:13AM  [$$] The Heated Quest for Opioid Alternatives The Wall Street Journal
09:51AM  Dow 30 Stock Roundup: GE's Transportation Unit to Merge With Wabtec, J&J & Glaxo's HIV Drug Gets EU Approval Zacks
12:30AM  Australian anti-trust watchdog loses appeal against Pfizer over Lipitor sales Reuters
May-24-18 11:59PM  [$$] Pfizer to Pay $24 Million to Settle Probe Into Copay Assistance Charities The Wall Street Journal
09:17PM  Pfizer to pay $23.85 million to settle U.S. co-payment kickback probe Reuters
05:02PM  Pfizer to pay $23.85 million to settle U.S. co-payment kickback probe Reuters
02:29PM  [$$] Pfizer to Pay $24 Million to Settle Probe Into Copay Assistance Charities The Wall Street Journal
01:23PM  Pfizer Used Charity to Mask Heart Drug Price Hikes, U.S. Says Bloomberg
12:12PM  Pfizer to pay $23.85 million to settle kickback allegations MarketWatch
11:08AM  Pfizer's Tafamadis Gets Breakthrough Therapy Designation Zacks
10:48AM  Pfizer to pay $23.85 million to resolve U.S. kickbacks case Reuters
10:19AM  Drug maker Pfizer to pay $23.85 mln to settle claims it paid kickbacks Reuters
10:19AM  Pfizer to pay $23.85 million to resolve U.S. kickbacks case Reuters
10:18AM  3 Top Biosimilars that Will Lift Pfizer Inc. Stock Even More InvestorPlace
09:28AM  3 Big Pharma Stocks with Huge Future Growth Potential InvestorPlace
07:15AM  Wired News - Spark Therapeutics and Pfizer Announced Positive Data from Phase-1/2 Clinical Trial of SPK-9001 for Haemophilia B Treatment ACCESSWIRE
12:15AM  [$$] Pfizer under pressure to resolve shortage of life-saving EpiPen Financial Times
May-23-18 10:39PM  [$$] Pfizer agrees to pay nearly $24m to settle kickback claims Financial Times
06:32PM  Trump Administration Ups Dose Of Shame As TV Drug Ad Policy Idea Moves Forward TheStreet.com
08:00AM  FDA Grants Breakthrough Therapy Designation for Tafamidis for the Treatment of Patients with Transthyretin Cardiomyopathy Business Wire
06:01AM  Better Buy: AbbVie Inc. vs. Pfizer Inc. Motley Fool
May-22-18 01:30PM  A Study Analyzing Observational Data Shows Real-World Effectiveness of Prevnar® 13 in Adults Age 65+ Business Wire
11:43AM  Spark, Pfizer report progress on gene therapy for hemophilia American City Business Journals
08:00AM  Pfizer Begins a Phase 1/2 Study to Evaluate Respiratory Syncytial Virus (RSV) Vaccine Business Wire
02:01AM  Spark Therapeutics and Pfizer Announce Data from 15 Participants with Hemophilia B Showing Persistent and Sustained Factor IX Levels with No Serious Adverse Events GlobeNewswire
May-21-18 06:11AM  ViiV Healthcare Receives EU Marketing Authorisation for Juluca (dolutegravir/rilpivirine), the First 2-Drug Regimen, Once-Daily, Single-Pill for the Treatment of HIV Business Wire
May-18-18 03:21PM  Pfizer's Epilepsy Drug Lyrica Succeeds in Pediatric Study Zacks
02:35PM  Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug Zacks
01:35AM  [$$] AstraZeneca chief Pascal Soriot suffers pay revolt Financial Times
May-17-18 04:51PM  Invacare Corporation Appoints Petra Danielsohn-Weil, PhD, to Board of Directors Business Wire
11:27AM  Investors Need to Adopt a Different Mindset for Big Pharma and Biotech Stocks InvestorPlace
10:38AM  Sangamo Therapeutics Stock History Motley Fool
10:03AM  Roche Tecentriq Combo Achieves Longer Overall Survival Rate Zacks
09:35AM  Exelixis' Cabometyx Gets EU Nod for First-Line Kidney Cancer Zacks
08:00AM  LYRICA® (pregabalin) Oral Solution CV Phase 3 Trial in Pediatric Epilepsy Meets Primary Endpoint Business Wire
Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care. This segment offers products primarily under the Prevnar 13/Prevenar 13, Xeljanz, Eliquis, Lyrica, Enbrel, Ibrance, Xtandi, Advil, and Centrum brands. The EH segment offers products that would lose or have lost marketing patent protection; branded generic products; generic sterile injectable products; biosimilars; and anti-infectives. It provides products under the Lipitor, Premarin family, Norvasc, Lyrica, Celebrex, Viagra, Inflectra/Remsima, Pristiq, Zyvox, Vfend, Revatio, Inspra, Medrol, Sulperazon, Fragmin, Tygacil, Nivestim, and Retacrit brand names. This segment also engages in the research and development, as well as contract manufacturing activities. Pfizer Inc. has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company for the development of Eliquis; Astellas Pharma US, Inc. for developing Xtandi; Merck KGaA for the development of Bavencio; and Neofluidics, LLC to develop a microfluidics-based platform. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
OLSON LAURIE JExecutive Vice PresidentJun 06Sale36.4519,000692,58282,886Jun 08 01:11 PM
CORNWELL W DONDirectorJun 04Sale36.405,223190,1170Jun 05 04:44 PM
READ IAN CChairman & CEOMay 01Sale36.01132,3124,764,0811,144,703May 03 04:19 PM
JOHNSON RADY AExecutive Vice PresidentMar 13Sale36.5527,323998,66643,178Mar 14 05:19 PM
LANKLER DOUGLAS MExecutive Vice PresidentMar 13Sale36.8950,0001,844,39883,857Mar 14 05:13 PM
Dolsten MikaelPresident R&DMar 09Sale36.5969,6992,550,39451,185Mar 12 05:01 PM
HILL CHARLES HExecutive Vice PresidentMar 06Sale35.7642,3931,515,98557,328Mar 07 04:09 PM
Dolsten MikaelPresident R&DMar 02Sale35.8513,986501,398120,884Mar 05 09:23 AM
SUSMAN SALLYExecutive Vice PresidentFeb 28Option Exercise27.37110,1323,014,313245,362Mar 02 04:03 PM
BOURLA ALBERTChief Operating OfficerFeb 28Option Exercise27.3739,9231,092,693184,120Mar 02 03:24 PM
YOUNG JOHN DGroup PresidentFeb 28Option Exercise27.37121,1453,315,739362,707Mar 02 04:10 PM
READ IAN CChairman & CEOFeb 28Option Exercise27.37649,78017,784,4791,774,184Mar 02 04:03 PM
Lewis-Hall Freda CExecutive Vice PresidentFeb 28Option Exercise27.37104,6262,863,614384,219Mar 02 03:44 PM
OLSON LAURIE JExecutive Vice PresidentFeb 28Option Exercise27.3738,5461,055,004132,702Mar 02 04:02 PM
JOHNSON RADY AExecutive Vice PresidentFeb 28Option Exercise27.3719,273527,50285,910Mar 02 03:44 PM
LANKLER DOUGLAS MExecutive Vice PresidentFeb 28Option Exercise27.3746,8061,281,080171,276Mar 02 03:44 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 28Option Exercise27.37209,2515,727,200655,161Mar 02 03:24 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerFeb 28Option Exercise27.3733,040904,305136,847Mar 02 03:24 PM
Dolsten MikaelPresident R&DFeb 28Option Exercise27.37198,2385,425,774293,352Mar 02 03:24 PM
HILL CHARLES HExecutive Vice PresidentFeb 28Option Exercise27.37101,8722,788,237207,942Mar 02 03:24 PM
LUND-JURGENSEN KIRSTENExecutive Vice PresidentFeb 28Option Exercise27.3719,273527,50239,801Mar 02 03:44 PM
HILL CHARLES HExecutive Vice PresidentFeb 28Sale36.8326,779986,292181,163Mar 02 03:24 PM
Dolsten MikaelPresident R&DFeb 27Sale37.0464,5872,392,31395,114Feb 28 06:04 PM
SUSMAN SALLYExecutive Vice PresidentFeb 27Sale37.0333,3681,235,591135,230Feb 28 06:14 PM
CORNWELL W DONDirectorFeb 27Sale37.0530011,1150Feb 28 01:29 PM
LUND-JURGENSEN KIRSTENExecutive Vice PresidentFeb 26Sale37.199,510353,67717,770Feb 27 07:38 PM
CORNWELL W DONDirectorFeb 26Sale36.741,45853,5640Feb 28 01:29 PM
YOUNG JOHN DGroup PresidentFeb 24Option Exercise18.9043,520822,528223,733Feb 27 08:59 PM
JOHNSON RADY AExecutive Vice PresidentFeb 24Option Exercise18.9015,885300,22762,848Feb 27 07:43 PM
HILL CHARLES HExecutive Vice PresidentFeb 24Option Exercise18.9065,2801,233,792122,609Feb 27 07:38 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerFeb 24Option Exercise18.9028,288534,643116,769Feb 27 07:30 PM
SUSMAN SALLYExecutive Vice PresidentFeb 24Option Exercise18.9091,8761,736,456206,972Feb 27 07:51 PM
Lewis-Hall Freda CExecutive Vice PresidentFeb 24Option Exercise18.9091,8761,736,456313,499Feb 27 07:43 PM
MACKENZIE ALEXANDER RExecutive Vice PresidentFeb 24Option Exercise18.9039,555747,590143,152Feb 27 07:38 PM
Dolsten MikaelPresident R&DFeb 24Option Exercise18.90174,0813,290,131225,265Feb 27 07:32 PM
BOURLA ALBERTChief Operating OfficerFeb 24Option Exercise18.9025,387479,814158,170Feb 27 07:30 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 24Option Exercise18.90174,0813,290,131511,470Feb 27 07:30 PM
OLSON LAURIE JExecutive Vice PresidentFeb 24Option Exercise18.9015,716297,03290,222Feb 27 07:53 PM
LANKLER DOUGLAS MExecutive Vice PresidentFeb 24Option Exercise18.9028,288534,643112,081Feb 27 07:43 PM
LUND-JURGENSEN KIRSTENExecutive Vice PresidentFeb 24Option Exercise18.9015,957301,58736,959Feb 27 07:38 PM
READ IAN CChairman & CEOFeb 24Option Exercise19.83903,55917,917,2651,560,007Feb 27 08:58 PM
JOHNSON RADY AExecutive Vice PresidentDec 15Sale37.078,000296,56046,963Dec 18 06:17 PM
MACKENZIE ALEXANDER RExecutive Vice PresidentDec 15Sale37.006,750249,750103,458Dec 18 06:17 PM
MACKENZIE ALEXANDER RExecutive Vice PresidentNov 01Sale34.947,350256,809110,082Nov 02 07:03 PM
PFIZER INC10% OwnerOct 10Buy17.0040,000680,0001,427,639Oct 10 04:22 PM
MACKENZIE ALEXANDER RExecutive Vice PresidentOct 02Sale35.657,350262,028117,432Nov 02 07:03 PM
SUSMAN SALLYExecutive Vice PresidentSep 12Sale35.0038,2301,338,050115,096Sep 14 09:13 AM
MACKENZIE ALEXANDER RExecutive Vice PresidentSep 01Sale34.007,350249,900124,774Sep 05 06:15 PM
DAMELIO FRANK AExecutive Vice PresidentAug 31Sale34.0094,4093,209,906337,389Sep 01 06:37 PM
READ IAN CChairman & CEOAug 31Sale34.0055,9751,903,150580,318Sep 01 06:37 PM
READ IAN CChairman & CEOAug 31Sale34.00141,1934,800,56280,762Sep 01 06:37 PM
MACKENZIE ALEXANDER RExecutive Vice PresidentAug 31Sale34.007,350249,900132,124Sep 01 06:37 PM
OLSON LAURIE JExecutive Vice PresidentAug 21Sale32.708,064263,69374,506Aug 23 03:51 PM
MACKENZIE ALEXANDER RExecutive Vice PresidentAug 07Sale33.5015,000502,560139,474Aug 09 05:00 PM
READ IAN CChairman & CEOAug 04Sale34.0068,8342,340,356221,955Aug 08 05:02 PM
READ IAN CChairman & CEOAug 04Sale34.0028,116955,944636,293Aug 08 05:02 PM